Slaughter and May is advising GlaxoSmithKline plc (GSK) on a series of agreements with the Aspen Group (Aspen) as part of GSK’s strategy of simplification through focusing on core therapeutic areas. GSK will divest its anaesthesia portfolio to Aspen for £180 million plus milestones of up to £100 million. GSK and Aspen have also entered into parallel agreements to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets. The agreements are subject to regulatory and anti-trust approvals.

Slaughter and May is supporting the GSK legal team which is led by Elizabeth Planell and Katie Salmon.
Contacts

Corporate: Richard Smith (partner), Chris McGaffin (partner), David Johnson (partner), Claire Jackson (associate), Christopher Tolley (associate), Gretel Scott (trainee); Intellectual Property: Susie Middlemiss (partner), Cathy Connolly (partner), Laura Houston (associate), Sarah Mateen (associate); Tax: Dominic Robertson (partner), Orlaith Kane (associate); Competition: Jordan Ellison (partner), Kerry O’Connell (associate), Lorna Nsoatabe (associate); Pensions and Employment: Sandeep Maudgil (partner), Simon Clark (associate), Rosemary Nelson (associate)